Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

#Artificial Intelligence (AI)-Powered Clinical Trial Site Feasibility Market Size And Revenue Forecast Through 2030

The market for deep learning in drug discovery and diagnostics has seen exponential expansion in recent years. Projections indicate it will increase from $10.58 billion in 2025 to $13.61 billion in 2026, achieving a compound annual growth rate (CAGR) of 28.7%. The historic period’s growth can be explained by the greater accessibility of extensive biomedical datasets, enhanced computational capabilities for training models, broader integration of AI into pharmaceutical research and development, an increased need for quicker drug discovery timelines, and the initial effectiveness of deep learning-based diagnostic systems.

The deep learning market within drug discovery and diagnostics is projected to experience robust expansion during the coming years. By 2030, its value is anticipated to reach $36.96 billion, reflecting a compound annual growth rate (CAGR) of 28.4%. This upward trajectory in the forecast period is driven by factors such as heightened investments in AI-powered healthcare solutions, a growing demand for precision medicine, broader incorporation of artificial intelligence into clinical workflows, increased utilization of real-world evidence data, and rising regulatory endorsement of AI-assisted diagnostic tools. Significant trends shaping this period encompass the widespread application of deep neural networks for drug screening, the growing reliance on AI-driven predictive modeling in diagnostics, the expanding incorporation of multi-omics data analysis, the proliferation of automated clinical decision support systems, and a stronger emphasis on personalized medicine platforms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28137&type=smp

Artificial Intelligence (AI)-Powered Clinical Trial Site Feasibility Market Opportunity Drivers: What Is Creating New Revenue Potential?

The increasing need for customized treatments is set to propel advancements in the market for deep learning in drug discovery and diagnostics. Personalized medicine adapts medical care to individual genetic, environmental, and lifestyle profiles, aiming to boost effectiveness while reducing negative effects. This rising demand is fueled by progress in genomics and data analysis, which allow for more targeted and accurate therapies tailored to each patient’s distinct characteristics. In this context, deep learning improves personalized medicine by processing intricate biological data to highlight specific biomarkers and more reliably forecast how patients will respond to treatments. For example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the United States, reported that the FDA greenlit 16 new personalized therapies for individuals with rare conditions in 2023, up from just six in 2022. Hence, the growing preference for personalized medicine is driving the expansion of the deep learning in drug discovery and diagnostics market.

Artificial Intelligence (AI)-Powered Clinical Trial Site Feasibility Market Segment Landscape: Which Areas Lead Market Development?

The computer-aided drug discovery market covered in this report is segmented –

1) By Type: Structure Based Drug Design, Ligand-Based Drug Design, Sequence-Based Approaches

2) By Therapeutic Area: Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes, Other Therapeutic Areas

3) By End User: Pharmaceutical Companies, Biotechnology Companies, Research Laboratories

Subsegments:

1) By Structure Based Drug Design: X-ray Crystallography, Nuclear Magnetic Resonance (NMR) Spectroscopy, Molecular Docking Studies, Virtual Screening

2) By Ligand-Based Drug Design: Quantitative Structure-Activity Relationship (QSAR) Models, Pharmacophore Modeling, Ligand Similarity Searching, Fragment-Based Drug Design

3) By Sequence-Based Approaches: Protein Structure Prediction, Homology Modeling, Bioinformatics for Drug Target Identification, Genomic Data Analysis for Drug Discovery

Artificial Intelligence (AI)-Powered Clinical Trial Site Feasibility Market Innovation Trends Driving Future Development

Major players in the deep learning drug discovery and diagnostics market are integrating cutting-edge technologies such as generative artificial intelligence (AI) and machine-learning (ML)-powered automation platforms to boost efficiency, cut research and development (R&D) expenses, and expedite the identification of early-stage treatments. These generative AI and ML-driven automation platforms are computational systems that analyze chemical and biological datasets to generate new drug candidates in silico, forecast molecular properties, and streamline the synthesis and testing of compounds via robotic systems, thus decreasing dependence on conventional high-throughput screening methods. A case in point is July 2024, when Exscientia, a UK-based AI-focused drug design firm, unveiled its AWS-hosted AI/ML platform. This system pairs a “DesignStudio” for AI-powered molecule creation with an “AutomationStudio” for robotic lab synthesis and evaluation. Functioning within a closed “design–make–test–learn” cycle, experimental results continuously enhance the AI models, markedly hastening discovery, expanding scalability, and facilitating more precise and cost-effective development of innovative therapies.

Artificial Intelligence (AI)-Powered Clinical Trial Site Feasibility Market Industry Leaders And Market Competition

Major companies operating in the computer-aided drug discovery market are Dassault Systèmes SE, PerkinElmer Inc., Roivant Sciences Ltd., Certara Inc., Schrödinger Inc., XtalPi Inc., Dotmatics Limited, Simulations Plus Inc., ChemAxon Ltd., Exscientia Ltd., Insilico Medicine Inc., Collaborative Drug Discovery Inc., OpenEye Scientific Software Inc., Nimbus Therapeutics LLC, Atomwise Inc., GNS Healthcare Inc., BenevolentAI Limited, EpiVax Inc., Numerate Inc., Cloud Pharmaceuticals Inc., Aris Pharmaceuticals Inc., Cyclica Inc., BioSolveIT GmbH, Chemical Computing Group ULC, InSilicoTrials Technologies S.p.A

Access The Complete Artificial Intelligence (AI)-Powered Clinical Trial Site Feasibility Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-powered-clinical-trial-site-feasibility-global-market-report

Artificial Intelligence (AI)-Powered Clinical Trial Site Feasibility Market Geographic Distribution And Regional Opportunities

North America was the largest region in the computer-aided drug discovery (CADD) market in 2025. The regions covered in the computer-aided drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Artificial Intelligence (AI)-Powered Clinical Trial Site Feasibility Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=28934&type=smp

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model